151 related articles for article (PubMed ID: 23802423)
1. Enzyme-entrapped mesoporous silica for treatment of uric acid disorders.
Muthukoori S; Narayanan N; Chandra MS; Sethuraman S; Krishnan UM
J Biomed Nanotechnol; 2013 May; 9(5):907-14. PubMed ID: 23802423
[TBL] [Abstract][Full Text] [Related]
2. Urate crystal degradation for treatment of gout: a nanoparticulate combination therapy approach.
Tiwari S; Dwivedi H; Kymonil KM; Saraf SA
Drug Deliv Transl Res; 2015 Jun; 5(3):219-30. PubMed ID: 25787730
[TBL] [Abstract][Full Text] [Related]
3. Pegloticase: a novel agent for treatment-refractory gout.
Shannon JA; Cole SW
Ann Pharmacother; 2012 Mar; 46(3):368-76. PubMed ID: 22395256
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.
Sundy JS; Ganson NJ; Kelly SJ; Scarlett EL; Rehrig CD; Huang W; Hershfield MS
Arthritis Rheum; 2007 Mar; 56(3):1021-8. PubMed ID: 17328081
[TBL] [Abstract][Full Text] [Related]
5. Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout.
Biggers K; Scheinfeld N
Curr Opin Investig Drugs; 2008 Apr; 9(4):422-9. PubMed ID: 18393109
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
Sundy JS; Baraf HS; Yood RA; Edwards NL; Gutierrez-Urena SR; Treadwell EL; Vázquez-Mellado J; White WB; Lipsky PE; Horowitz Z; Huang W; Maroli AN; Waltrip RW; Hamburger SA; Becker MA
JAMA; 2011 Aug; 306(7):711-20. PubMed ID: 21846852
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure gout.
Yue CS; Huang W; Alton M; Maroli AN; Waltrip RW; Wright D; Marco MD
J Clin Pharmacol; 2008 Jun; 48(6):708-18. PubMed ID: 18420531
[TBL] [Abstract][Full Text] [Related]
8. Pegloticase and the patient with treatment-failure gout.
Dave AJ; Kelly VM; Krishnan E
Expert Rev Clin Pharmacol; 2012 Sep; 5(5):501-8. PubMed ID: 23121270
[TBL] [Abstract][Full Text] [Related]
9. Pegloticase for treating refractory chronic gout.
George RL; Sundy JS
Drugs Today (Barc); 2012 Jul; 48(7):441-9. PubMed ID: 22844655
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic analysis of intravenous recombinant urate oxidase using an indirect pharmacological response model in healthy subjects.
Cai NF; Cheng ZN; Zi Y; Luo X; Guo X; Liu Z; Zheng LY
Acta Pharmacol Sin; 2014 Nov; 35(11):1447-52. PubMed ID: 25283504
[TBL] [Abstract][Full Text] [Related]
11. Characterization, efficacy, pharmacokinetics, and biodistribution of 5kDa mPEG modified tetrameric canine uricase variant.
Zhang C; Fan K; Luo H; Ma X; Liu R; Yang L; Hu C; Chen Z; Min Z; Wei D
Int J Pharm; 2012 Jul; 430(1-2):307-17. PubMed ID: 22503989
[TBL] [Abstract][Full Text] [Related]
12. Colchicine mesoporous silica nanoparticles/hydrogel composite loaded cotton patches as a new encapsulator system for transdermal osteoarthritis management.
Mohamed AL; Elmotasem H; Salama AAA
Int J Biol Macromol; 2020 Dec; 164():1149-1163. PubMed ID: 32693125
[TBL] [Abstract][Full Text] [Related]
13. Pegloticase and chronic gout.
Ea HK; Chales G; Lioté F
JAMA; 2011 Nov; 306(18):1979; author reply 1979-80. PubMed ID: 22068987
[No Abstract] [Full Text] [Related]
14. A Therapeutic Uricase with Reduced Immunogenicity Risk and Improved Development Properties.
Nyborg AC; Ward C; Zacco A; Chacko B; Grinberg L; Geoghegan JC; Bean R; Wendeler M; Bartnik F; O'Connor E; Gruia F; Iyer V; Feng H; Roy V; Berge M; Miner JN; Wilson DM; Zhou D; Nicholson S; Wilker C; Wu CY; Wilson S; Jermutus L; Wu H; Owen DA; Osbourn J; Coats S; Baca M
PLoS One; 2016; 11(12):e0167935. PubMed ID: 28002433
[TBL] [Abstract][Full Text] [Related]
15. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.
Ganson NJ; Kelly SJ; Scarlett E; Sundy JS; Hershfield MS
Arthritis Res Ther; 2006; 8(1):R12. PubMed ID: 16356199
[TBL] [Abstract][Full Text] [Related]
16. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.
Cammalleri L; Malaguarnera M
Int J Med Sci; 2007 Mar; 4(2):83-93. PubMed ID: 17396159
[TBL] [Abstract][Full Text] [Related]
17. Transdermal delivery of nicardipine: an approach to in vitro permeation enhancement.
Aboofazeli R; Zia H; Needham TE
Drug Deliv; 2002; 9(4):239-47. PubMed ID: 12511202
[TBL] [Abstract][Full Text] [Related]
18. Preparation of PEGylated uricase attached magnetic nanowires and application for uric acid oxidation.
Kilimci U; Uygun DA
J Biotechnol; 2023 Aug; 373():12-19. PubMed ID: 37343601
[TBL] [Abstract][Full Text] [Related]
19. [Gout: an overview of available urate lowering therapies].
Richette P
Ann Pharm Fr; 2012 May; 70(3):133-8. PubMed ID: 22655581
[TBL] [Abstract][Full Text] [Related]
20. Activity and stability of uricase from Lactobacillus plantarum immobilizated on natural zeolite for uric acid biosensor.
Iswantini D; Nurhidayat N; Trivadila ; Widiyatmoko O
Pak J Biol Sci; 2014 Jan; 17(2):277-81. PubMed ID: 24783814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
